JAGX · Jaguar Health, Inc.

Jaguar Health, Inc. faced dual Nasdaq compliance issues: the minimum 500,000 Publicly Held Shares Requirement under Listing Rule 5550(a)(4) and the $1.00 minimum bid price under Rule 5550(a)(2). On May 1, 2026, Nasdaq staff notified the company of non-compliance with the shares requirement, which also prolonged the bid price non-compliance period under Rule 5810(c)(3)(A). The company resolved the shares deficiency on May 4, 2026, through exercises of pre-funded warrants by third-party investors. This reset the compliance clock for the bid price rule. The Nasdaq Hearings Panel, in its May 6, 2026 decision, extended the deadline by one day to May 18, 2026, allowing Jaguar Health to demonstrate a closing bid price of at least $1.00 for 10 consecutive business days. This extension provides a narrow window to avoid delisting, critical for maintaining Nasdaq listing status and investor access. The company states it is diligently pursuing compliance, but explicitly warns of no guarantees, highlighting execution risk for shareholders.